Michael Zaiac, Switzerland



Vice President, Head of Haematology / Oncology Medical Affairs EMEA

Michael's responsibilities at Celgene encompass medical information, scientific communication and education, collaborative data generation and Celgene-sponsored studies operated by Medical Affairs across Celgene’s haematology and oncology franchise in the EMEA region 

Since joining the pharmaceutical Industry in 1994, Michael has  covered roles of increasing responsibility in clinical research, medical affairs and strategic marketing and participated in new medicines launches, large development programs for small molecules and monoclonal antibodies and the day-to-day management of medical affairs, research and commercialisation at country, regional and global level.  

Michael pursued a postgraduate career in Surgery and Surgical Oncology in the UK and in Germany gaining an MD in myocardial preservation in 1989 and an FRCS in 1992. He also gained an MBA in 1999, a specialist registration in pharmaceutical medicine in 2005 and is a fellow of the Faculty of Pharmaceutical Medicine at the Royal College of Physicians.

He has published scientific papers on surgery, breast cancer, sarcoma targeted small molecules, mToR and general aspects of pharmaceutical medicine. Michael's responsibilities at Celgene encompass medical information, scientific communication and education, collaborative data generation and Celgene-sponsored studies operated by Medical Affairs across Celgene’s haematology and oncology franchise in the EMEA region 


Since joining the pharmaceutical Industry in 1994, Michael has  covered roles of increasing responsibility in clinical research, medical affairs and strategic marketing and participated in new medicines launches, large development programs for small molecules and monoclonal antibodies and the day-to-day management of medical affairs, research and commercialisation at country, regional and global level.  


Michael pursued a postgraduate career in Surgery and Surgical Oncology in the UK and in Germany gaining an MD in myocardial preservation in 1989 and an FRCS in 1992. He also gained an MBA in 1999, a specialist registration in pharmaceutical medicine in 2005 and is a fellow of the Faculty of Pharmaceutical Medicine at the Royal College of Physicians.


He has published scientific papers on surgery, breast cancer, sarcoma targeted small molecules, mToR and general aspects of pharmaceutical medicine. 

Michael's responsibilities at Celgene encompass medical information, scientific communication and education, collaborative data generation and Celgene-sponsored studies operated by Medical Affairs across Celgene’s haematology and oncology franchise in the EMEA region 


Since joining the pharmaceutical Industry in 1994, Michael has  covered roles of increasing responsibility in clinical research, medical affairs and strategic marketing and participated in new medicines launches, large development programs for small molecules and monoclonal antibodies and the day-to-day management of medical affairs, research and commercialisation at country, regional and global level.  


Michael pursued a postgraduate career in Surgery and Surgical Oncology in the UK and in Germany gaining an MD in myocardial preservation in 1989 and an FRCS in 1992. He also gained an MBA in 1999, a specialist registration in pharmaceutical medicine in 2005 and is a fellow of the Faculty of Pharmaceutical Medicine at the Royal College of Physicians.


He has published scientific papers on surgery, breast cancer, sarcoma targeted small molecules, mToR and general aspects of pharmaceutical medicine. 

Michael's responsibilities at Celgene encompass medical information, scientific communication and education, collaborative data generation and Celgene-sponsored studies operated by Medical Affairs across Celgene’s haematology and oncology franchise in the EMEA region 


Since joining the pharmaceutical Industry in 1994, Michael has  covered roles of increasing responsibility in clinical research, medical affairs and strategic marketing and participated in new medicines launches, large development programs for small molecules and monoclonal antibodies and the day-to-day management of medical affairs, research and commercialisation at country, regional and global level.  


Michael pursued a postgraduate career in Surgery and Surgical Oncology in the UK and in Germany gaining an MD in myocardial preservation in 1989 and an FRCS in 1992. He also gained an MBA in 1999, a specialist registration in pharmaceutical medicine in 2005 and is a fellow of the Faculty of Pharmaceutical Medicine at the Royal College of Physicians.


He has published scientific papers on surgery, breast cancer, sarcoma targeted small molecules, mToR and general aspects of pharmaceutical medicine. 

Michael's responsibilities at Celgene encompass medical information, scientific communication and education, collaborative data generation and Celgene-sponsored studies operated by Medical Affairs across Celgene’s haematology and oncology franchise in the EMEA region 


Since joining the pharmaceutical Industry in 1994, Michael has  covered roles of increasing responsibility in clinical research, medical affairs and strategic marketing and participated in new medicines launches, large development programs for small molecules and monoclonal antibodies and the day-to-day management of medical affairs, research and commercialisation at country, regional and global level.  


Michael pursued a postgraduate career in Surgery and Surgical Oncology in the UK and in Germany gaining an MD in myocardial preservation in 1989 and an FRCS in 1992. He also gained an MBA in 1999, a specialist registration in pharmaceutical medicine in 2005 and is a fellow of the Faculty of Pharmaceutical Medicine at the Royal College of Physicians.


He has published scientific papers on surgery, breast cancer, sarcoma targeted small molecules, mToR and general aspects of pharmaceutical medicine. 

Michael's responsibilities at Celgene encompass medical information, scientific communication and education, collaborative data generation and Celgene-sponsored studies operated by Medical Affairs across Celgene’s haematology and oncology franchise in the EMEA region 


Since joining the pharmaceutical Industry in 1994, Michael has  covered roles of increasing responsibility in clinical research, medical affairs and strategic marketing and participated in new medicines launches, large development programs for small molecules and monoclonal antibodies and the day-to-day management of medical affairs, research and commercialisation at country, regional and global level.  


Michael pursued a postgraduate career in Surgery and Surgical Oncology in the UK and in Germany gaining an MD in myocardial preservation in 1989 and an FRCS in 1992. He also gained an MBA in 1999, a specialist registration in pharmaceutical medicine in 2005 and is a fellow of the Faculty of Pharmaceutical Medicine at the Royal College of Physicians.


He has published scientific papers on surgery, breast cancer, sarcoma targeted small molecules, mToR and general aspects of pharmaceutical medicine.